代谢相关脂肪性肝炎无创评估研究进展

摘要/Abstract

摘要： 代谢相关脂肪性肝病(MAFLD)已成为我国慢性肝病的首要病因,其进展期代谢相关脂肪性肝炎(MASH)受到广泛关注。目前,MASH诊断的金标准为肝穿刺活检,但因具有侵入性,临床应用受限。因此,建立可靠的MASH无创诊断方法是当前研究的重要方向。本文综述了近年来MASH无创指标的研究进展,旨在为临床早期识别与动态评估提供参考依据。

高岩昆, 陈姝延, 孙亚朦. 代谢相关脂肪性肝炎无创评估研究进展[J]. 肝脏, 2026, 31(4): 477-481.

/ 推荐

[1] 中华医学会肝病学分会. 代谢相关(非酒精性)脂肪性肝病防治指南(2024年版)[J]. 实用肝脏病杂志, 2024, 27(4): 494-510.
[2] Younossi Z M, Koenig A B, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes[J]. Hepatology, 2016, 64(1): 73-84.
[3] Loomba R, Lawitz E, Mantry P S, et al. The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: a randomized, phase 2 trial[J]. Hepatology, 2018, 67(2): 549-559.
[4] Tao L, Yang X, Ge C, et al. Integrative clinical and preclinical studies identify FerroTerminator1 as a potent therapeutic drug for MASH[J]. Cell Metab, 2024, 36(10): 2190-2206.e5.
[5] Lee J, Vali Y, Boursier J, et al. Accuracy of cytokeratin 18 (M30 and M65) in detecting non-alcoholic steatohepatitis and fibrosis: a systematic review and meta-analysis[J]. PLoS One, 2020, 15(9): e0238717.
[6] Pimentel C F, Jiang Z G, Otsubo T, et al. Poor inter-test reliability between CK18 kits as a biomarker of NASH[J]. Dig Dis Sci, 2016, 61(3): 905-912.
[7] Abdelhameed F, Kite C, Lagojda L, et al. Non-invasive scores and serum biomarkers for fatty liver in the era of metabolic dysfunction-associated steatotic liver disease (MASLD): a comprehensive review from NAFLD to MAFLD and MASLD[J]. Curr Obes Rep, 2024, 13(3): 510-531.
[8] Sanyal A J, Shankar S S, Yates K P, et al. Diagnostic performance of circulating biomarkers for non-alcoholic steatohepatitis[J]. Nat Med, 2023, 29(10): 2656-2664.
[9] Zhang X, Shen J, Man K, et al. CXCL10 plays a key role as an inflammatory mediator and a non-invasive biomarker of non-alcoholic steatohepatitis[J]. J Hepatol, 2014, 61(6): 1365-1375.
[10] Potoupni V, Georgiadou M, Chatzigriva E, et al. Circulating tumor necrosis factor-α levels in non-alcoholic fatty liver disease: a systematic review and a meta-analysis[J]. J Gastroenterol Hepatol, 2021, 36(11): 3002-3014.
[11] Gastaldelli A, Sabatini S, Carli F, et al. PPAR-γ-induced changes in visceral fat and adiponectin levels are associated with improvement of steatohepatitis in patients with NASH[J]. Liver Int, 2021, 41(11): 2659-2670.
[12] Gallego-Durán R, Ampuero J, Maya-Miles D, et al. Fibroblast growth factor 21 is a hepatokine involved in MASLD progression[J]. United European Gastroenterol J, 2024, 12(8): 1056-1068.
[13] Huang Y, Li J, Song S, et al. Blood metabolic panels for identifying significant fibrosis and inflammation in patients with MASLD[J]. Cell Rep Med,2026 Jan 20,7(1):102522.
[14] Gao F, He Q, Li G, et al. A novel quantitative ultrasound technique for identifying non-alcoholic steatohepatitis[J]. Liver Int, 2022, 42(1): 80-91.
[15] Suhimoto K, Moriyasu F, Dioguardi Burgio M, et al. US markers and necroinflammation, steatosis, and fibrosis in metabolic dysfunction-associated steatotic liver disease: the iLEAD study[J]. Radiology, 2024, 312(2): e233377.
[16] Lee D H, Cho E J, Bae J S, et al. Accuracy of two-dimensional shear wave elastography and attenuation imaging for evaluation of patients with nonalcoholic steatohepatitis[J]. Clin Gastroenterol Hepatol, 2021, 19(4): 797-805.e7.
[17] Jang J K, Lee E S, Seo J W, et al. Two-dimensional shear-wave elastography and US attenuation imaging for nonalcoholic steatohepatitis diagnosis: a cross-sectional, multicenter study[J]. Radiology, 2022, 305(1): 118-126.
[18] Pierce T T, Ozturk A, Sherlock S P, et al. Reproducibility and repeatability of US shear-wave and transient elastography in nonalcoholic fatty liver disease[J]. Radiology, 2024, 312(3): e233094.
[19] Pavlides M, Banerjee R, Tunnicliffe E M, et al. Multiparametric magnetic resonance imaging for the assessment of non-alcoholic fatty liver disease severity[J]. Liver Int, 2017, 37(7): 1065-1073.
[20] Alkhouri N, Beyer C, Shumbayawonda E, et al. Decreases in cT1 and liver fat content reflect treatment-induced histological improvements in MASH[J]. J Hepatol, 2025, 82(3): 438-445.
[21] Komiyama Y, Motosugi U, Maekawa S, et al. Early diagnosis of hepatic inflammation in Japanese nonalcoholic fatty liver disease patients using 3D MR elastography[J]. Hepatol Res, 2023, 53(3): 208-218.
[22] Allen A M, Shan V H, Therneau T M, et al. The role of three-dimensional magnetic resonance elastography in the diagnosis of nonalcoholic steatohepatitis in obese patients undergoing bariatric surgery[J]. Hepatology, 2020, 71(2): 510-521.
[23] Wu X X, Zheng K I, Boursier J, et al. acNASH index to diagnose nonalcoholic steatohepatitis: a prospective derivation and global validation study[J]. EClinicalMedicine, 2021, 41: 101145.
[24] Huang Q, Qadri S F, Bian H, et al. A metabolome-derived score predicts metabolic dysfunction-associated steatohepatitis and mortality from liver disease[J]. J Hepatol, 2025, 82(5): 781-793.
[25] Funada K, Kusano Y, Gyotoku Y, et al. Novel multi-parametric diagnosis of non-alcoholic fatty liver disease using ultrasonography, body mass index, and Fib-4 index[J]. World J Gastroenterol, 2023, 29(23): 3703-3714.
[26] Lee Y S, Lee J E, Yi H S, et al. MRE-based NASH score for diagnosis of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease[J]. Hepatol Int, 2022, 16(2): 316-324.
[27] Boursier J, Anty R, Vonghia L, et al. Screening for therapeutic trials and treatment indication in clinical practice: MACK-3, a new blood test for the diagnosis of fibrotic NASH[J]. Aliment Pharmacol Ther, 2018, 47(10): 1387-1396.
[28] Chuah K H, Wan Yusoff W N I, Sthaneshwar P, et al. MACK-3 (combination of hoMa, AST and CK18): a promising novel biomarker for fibrotic non-alcoholic steatohepatitis[J]. Liver Int, 2019, 39(7): 1315-1324.
[29] Huang X, Zhu T, Li S, et al. Development and validation of a non-invasive score for at-risk metabolic dysfunction-associated steatohepatitis in individuals with obesity undergoing bariatric surgery[J]. Hepatology, 2025 Nov 13.
[30] FDA. FDA accepts proposal for reasonably likely surrogate endpoint for ‘MASH’ all-cause mortality or liver-related events[EB/OL].(2025-08-27). https://www.fda.gov/drugs/drug-safety-and-availability/fda-accepts-proposal-reasonably-likely-surrogate-endpoint-mash-all-cause-mortality-or-liver-related
[31] Newsome P N, Sasso M, Deeks J J, et al. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study[J]. Lancet Gastroenterol Hepatol, 2020, 5(4): 362-373.
[32] Mózes F E, Lee J A, Vali Y, et al. Diagnostic accuracy of non-invasive tests to screen for at-risk MASH-An individual participant data meta-analysis[J]. Liver Int, 2024, 44(8): 1872-1885.
[33] Ravaioli F, Dajti E, Mantovani A, et al. Diagnostic accuracy of FibroScan-AST (FAST) score for the non-invasive identification of patients with fibrotic non-alcoholic steatohepatitis: a systematic review and meta-analysis[J]. Gut, 2023, 72(7): 1399-1409.
[34] Noureddin M, Truong E, Gornbein J A, et al. MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis[J]. J Hepatol, 2022, 76(4): 781-787.
[35] Feng G, Mózes F E, Ji D, et al. acFibroMASH Index for the diagnosis of Fibrotic MASH and prediction of liver-related events: an international multicenter study[J]. Clin Gastroenterol Hepatol, 2025, 23(5): 785-796.
[36] Fichez J, Mouillot T, Vonghia L, et al. Non-invasive tests for fibrotic MASH for reducing screen failure in therapeutic trials[J]. JHEP Rep, 2025, 7(4): 101351.
[37] Loomba R, Amangurbanova M, Bettencourt R, et al. MASH resolution index: development and validation of a non-invasive score to detect histological resolution of MASH[J]. Gut, 2024, 73(8): 1343-1349.
[38] Loomba R, Daniel P C N, Amangurbanova M, et al. Head-to-head comparison of MASH resolution index versus FAST for noninvasive prediction of resolution of MASH on biopsy[J]. Hepatology, 2026,83(4):907-914.
[39] Feng G, Boursier J, de Saint Loup M, et al. Fibrotic MASH resolutionVCTE index to diagnose fibrotic MASH resolution and predict LREs: a global multicenter study[J]. Med, Published online December 22, 2025.

代谢相关脂肪性肝炎无创评估研究进展

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	杨新月, 倪文婧, 陈楠, 李婕. 代谢相关脂肪性肝炎药物治疗研究进展与挑战[J]. 肝脏, 2026, 31(3): 304-311.
[2]	李健, 张雅楠, 黄肖雨, 王志华, 郄兰霞, 牛宏垚. 不同病理分型慢性药物性肝损伤患者临床及血清学特征对比研究[J]. 肝脏, 2026, 31(3): 394-400.
[3]	冯巩, 李如欣, 党焓悦, 李文彤, 弥曼, 陈敏, 严琴琴. 儿童代谢相关性脂肪肝的无创诊断研究进展[J]. 肝脏, 2025, 30(9): 1292-1295.
[4]	方莹, 李武. miR-33a在代谢相关脂肪性肝病中的研究进展[J]. 肝脏, 2025, 30(5): 742-746.
[5]	孙微, 余虹, 牛丽娜, 隆强, 窦靖, 刘云霄, 郭峰, 王晓忠. 肝脏硬度-脾脏直径/血小板比率等无创诊断指标对肝硬化高危食管静脉曲张的预测价值[J]. 肝脏, 2025, 30(3): 310-315.
[6]	杨瑜婧, 刘立业, 杨慧芳, 鄂楠, 王震侠. ALBI、Caspase-4联合肿瘤ADC值对原发性肝癌患者TACE术后复发的预测价值[J]. 肝脏, 2025, 30(12): 1637-1641.
[7]	任世呈, 吴旭, 李雪, 刘若男, 苏比努尔·库尔班, 窦婧, 张荣, 王晓忠. 代谢相关脂肪性肝病患者肝纤维化无创诊断研究进展[J]. 肝脏, 2025, 30(12): 1739-1742.
[8]	曾昊天, 李旭涛, 王四园, 阮天音, 陶艳艳, 冉云. 扶正化瘀方对代谢相关脂肪性肝炎的作用机制[J]. 肝脏, 2025, 30(11): 1534-1541.
[9]	余虹, 郭峰, 笪欣. 影像学及机器学习在代谢功能障碍相关脂肪性肝病中的应用价值[J]. 肝脏, 2025, 30(11): 1577-1579.
[10]	邱原元, 张敏, 项伟艳. 基于超声造影定量参数、超声血流参数构建肝硬化并发门静脉血栓的诊断模型[J]. 肝脏, 2024, 29(8): 905-909.
[11]	胡静, 易庭庄, 农欣蕾, 王统华. 血清学指标联合Child-Pugh评分对肝硬化食管静脉曲张破裂出血患者EVL术后再出血的预测价值[J]. 肝脏, 2024, 29(8): 934-938.
[12]	廖忠阳, 李杭, 陈泳松. 不同分子亚型肝细胞腺瘤影像学表现[J]. 肝脏, 2024, 29(8): 960-964.
[13]	高硕玉, 张秦, 张帅, 姚博悰. 药物性胆汁淤积型肝损伤患者的临床表现、影像学特征以及转归[J]. 肝脏, 2024, 29(8): 971-974.
[14]	饶晨怡, 李锋. 无创评估肝硬化门静脉高压严重程度的研究进展[J]. 肝脏, 2024, 29(7): 877-880.
[15]	刘婷, 杨金雨, 刘倩玉, 杨青. 全氟丁烷超声造影联合CEUS LI-RADS对肝细胞癌的诊断价值[J]. 肝脏, 2024, 29(4): 391-394.